AAAAAA
Results:
1-12
|
Results: 12
Authors:
Khuri, FR
Herbst, RS
Fossella, FV
Citation: Fr. Khuri et al., Emerging therapies in non-small-cell lung cancer, ANN ONCOL, 12(6), 2001, pp. 739-744
Authors:
Komaki, R
Chasen, MH
Travis, WD
Putnam, JB
Fossella, FV
Byhardt, RW
Ro, JY
Citation: R. Komaki et al., Oncodiagnosis panel: 1999 cancer of the lung: Oncodiagnosis, RADIOGRAPHI, 21(6), 2001, pp. 1573-1596
Authors:
Shepherd, FA
Fossella, FV
Lynch, T
Armand, JP
Rigas, JR
Kris, MG
Citation: Fa. Shepherd et al., Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials, SEMIN ONCOL, 28(1), 2001, pp. 4-9
Authors:
Fossella, FV
DeVore, R
Kerr, RN
Crawford, J
Natale, RR
Dunphy, F
Kalman, L
Miller, V
Lee, JS
Moore, M
Gandara, D
Karp, D
Vokes, E
Kris, M
Kim, Y
Gamza, F
Hammershaimb, L
Citation: Fv. Fossella et al., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated withplatinum-containing chemotherapy regimens, J CL ONCOL, 18(12), 2000, pp. 2354-2362
Authors:
Komaki, R
Roth, JA
Walsh, GL
Putnam, JB
Vaporciyan, A
Lee, JS
Fossella, FV
Chasen, M
Delclos, ME
Cox, JD
Citation: R. Komaki et al., Outcome predictors for 143 patients with superior sulcus tumors treated bymultidisciplinary approach at the University of Texas M. D. Anderson Cancer Center, INT J RAD O, 48(2), 2000, pp. 347-354
Authors:
Oh, Y
Perez-Soler, R
Fossella, FV
Glisson, BS
Kurie, J
Walsh, GL
Truong, M
Shin, DM
Citation: Y. Oh et al., Phase II study of intravenous Doxil (R) in malignant pleural mesothelioma, INV NEW DR, 18(3), 2000, pp. 243-245
Authors:
Liu, NS
Spitz, MR
Kemp, BL
Cooksley, C
Fossella, FV
Lee, JS
Hong, WK
Khuri, FR
Citation: Ns. Liu et al., Adenocarcinoma of the lung in young patients - The M. D. Anderson experience, CANCER, 88(8), 2000, pp. 1837-1841
Authors:
Glisson, BS
Kurie, JM
Perez-Soler, R
Fox, NJ
Murphy, WK
Fossella, FV
Lee, JS
Ross, MB
Nyberg, DA
Pisters, KMW
Shin, DM
Hong, WK
Citation: Bs. Glisson et al., Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma, J CL ONCOL, 17(8), 1999, pp. 2309-2315
Authors:
Fossella, FV
Citation: Fv. Fossella, Docetaxel in the treatment of non-small cell lung cancer: Review of single-agent trials, SEMIN ONCOL, 26(5), 1999, pp. 17-23
Authors:
Fossella, FV
Green, MR
Eckardt, JR
Wozniak, AJ
Socinski, MA
Murren, JR
Citation: Fv. Fossella et al., Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer - Discussion I, SEMIN ONCOL, 26(5), 1999, pp. 41-42
Authors:
Fossella, FV
Citation: Fv. Fossella, Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer, SEMIN ONCOL, 26(3), 1999, pp. 4-8
Authors:
Fossella, FV
Rigas, J
Citation: Fv. Fossella et J. Rigas, The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens, SEMIN ONCOL, 26(3), 1999, pp. 9-12
Risultati:
1-12
|